Structural membrane alterations in Alzheimer brains found to be associated with regional disease development; increased density of gangliosides GM1 and GM2 and loss of cholesterol in detergent-resistant membrane domains

Journal of Neurochemistry

Volumn 92, Issue 1, 2005, Pages 171-182

  Molander Melin, Marie ^a   Blennow, Kaj ^a   Bogdanovic, Nenad ^b   Dellheden, Birgitta ^a   Månsson, Jan Eric ^a   Fredman, Pam ^a,c  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Alzheimer; Beta amyloid; Gangliosides; GM1; Lipids; Rafts

Indexed keywords

GANGLIOSIDE GD 1A; GANGLIOSIDE GD 1B; GANGLIOSIDE GD2; GANGLIOSIDE GM1; GLYCEROPHOSPHOLIPID;

AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; CELL DENSITY; CELL FUNCTION; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MEMBRANE DAMAGE; MEMBRANE STRUCTURE; PRIORITY JOURNAL; TEMPORAL CORTEX;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CEREBRAL CORTEX; CHOLESTEROL; DETERGENTS; FEMALE; FRONTAL LOBE; G(M2) ACTIVATOR PROTEIN; HUMANS; MALE; MEMBRANE LIPIDS; MEMBRANE MICRODOMAINS; MIDDLE AGED; SPHINGOLIPID ACTIVATOR PROTEINS; TEMPORAL LOBE;

EID: 13244272410     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2004.02849.x     Document Type: Article

References (65)

1. Alafuzoff I., Iqbal K., Fridén H., Adolfsson R. and Winblad B. (1987) Histopathological criteria for progressive dementia disorders: clinical-pathological correlation and classification by multivariate data analysis. Acta Neuropathol. 74, 209-225.
2. Anderson R. G. and Jacobson K. (2002) A role for lipid shells in targeting proteins to caveolae, rafts, and other lipid domains. Science 296, 1821-1825.
3. Ando S. (1983) Gangliosides in the nervous system. Neurochem. Int. 5, 507-537.
4. Blennow K., Davidsson P., Wallin A., Fredman P., Gottfries C. G., Mansson J. E. and Svennerholm L. (1991a) Gangliosides in cerebrospinal fluid in 'probable Alzheimer's disease'. Arch. Neurol. 48, 1032-1035.
5. Blennow K., Wallin A. and Gottfries C.-G. (1991b) Presence of parieto-temporal symptomatology distinguishes early and late onset Alzheimer's disease. Int. J. Geriatr Psychiatry 6, 147-154.
6. Brown D. A. and Rose J. K. (1992) Sorting of GPI-anchored proteins to glycolipid-enriched membrane subdomains during transport to the apical surface. Cell 68, 533-544.
7. Bums M. and Duff K. (2002) Cholesterol in Alzheimer's disease and Tauopathy. Ann. N.Y. Acad. Sci. 977, 367-375.
8. Choo-Smith L.-P., Garzon-Rodriguez W., Glabe C. and Surewicz W. (1997) Acceleration of amyloid fibril formation by specific binding of Aβ-(1-40) peptide to ganglioside-containing membrane vesicles. J. Biol. Chem. 272, 22 987-22 990.
9. Cossy-Isasi S. and Panzetta P. (1994) In vitro changes of ganglioside immunostain localization in developing neural cells. Neurochem. Int. 24, 323-328.
10. Crawford N. (1958) An important method for the determination of free and total cholesterol using ferric chloride reaction. Clin. Chim. Acta 3, 357-367.
11. Davidsson P. and Blennow K. (1998) Neurochemical dissection of synaptic pathology in Alzheimer's disease. Int. Psychogeriatr. 10, 11-23.
12. Davidsson P., Fredman P., Månsson J.-E. and Svennerholm L. (1991) Determination of gangliosides and sulfatide in human cerebrospinal fluid with a microimmunoaffinity technique. Clin. Chim. Acta 197, 105-115.
13. Ehehalt R., Keller P., Haass C., Thiele C. and Simons K. (2003) Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J. Cell Biol. 160, 113-123.
14. Gibson Wood W., Eckert G. P., Igbavboa U. and Müller W. E. (2003) Amyloid beta-protein interactions with membranes and cholesterol: causes or casualties of Alzheimer's disease (review). Biochim. Biophys. Acta 1610, 281-290.
15. Gottfries C. G., Karlsson I. and Svennerholm L. (1996) Membrane components separate early-onset Alzheimer's disease from senile dementia of the Alzheimer type. Int. Psychogeriatr. 8, 365-372.
16. Hakomori S. (1991) New directions in cancer therapy based on aberrant expression of glycosphingolipids: anti-adhesion and ortho-signaling therapy. Cancer Cells 3, 461-470.
17. Hakomori S. I. (2000) Cell adhesion/recognition and signal transduction through glycosphingolipid microdomain. Glycoconj. J. 17, 143-151.
18. Iwamoto N., Suzuki Y., Makino Y., Haga C., Kosaka K. and Iizuka R. (1990) Cell membrane changes in brains manifistating senile plaques: an immunohistochemical study of GM1 membranous ganglioside. Brain Res. 522, 152-156.
19. Kakio A., Nishimoto S. I., Yanagisawa K., Kozutsumi Y. and Matsuzaki K. (2001) Cholesterol-dependent formation of GM1 ganglioside-bound amyloid beta-protein, an endogenous seed for Alzheimer amyloid. J. Biol. Chem. 276, 24 985-24 990.
20. Kakio A., Nishimoto S.-I., Yanagisawa K., Kozutsumi Y. and Matsuzaki K. (2002) Interactions of amyloid β-protein with various gangliosides in raft-like membranes: importance of GM1 ganglioside-bound form as an endogenous seed for Alzheimer amyloid. Biochemistry 41, 7385-7390.
21. Kakio A., Nishimoto S.-I., Kozutsumi Y. and Matsuzaki K. (2003) Formation of a membrane-active form of amyloid β-protein in raft-like model membranes. Biochem. Biophys. Res. Commun. 303, 514-518.
22. Karlsson G., Mansson J. E., Wikstrand C., Bigner D. and Svennerholm L. (1990) Characterization of the binding epitope of the monoclonal antibody DMAb-1 to ganglioside GM2. Biochim. Biophys. Acta 1043, 267-272.
23. Kolsch H., Lutjohann D., von Bergmann K. and Heun R. (2003) The role of 24 hydroxycholesterol in Alzheimer's disease. J. Nutr. Health Aging 7, 37-41.
24. Kotani M., Kawashima I., Ozawa H., Terashima T. and Tai T. (1993) Differential distribution of major gangliosides in rat central nervous system detected by specific monoclonal antibodies. Glycobiology 3, 137-146.
25. Kracun I., Kalanj S., Talan-Hranilovic J. and Cosovic C. (1992) Cortical distribution of gangliosides in Alzheimer's disease. Neurochem. Int. 20, 433-438.
26. Lai E. C. (2003) Lipid rafts make for slippery platforms. J. Cell Biol. 162, 365-370.
27. Ledeen R. (1985) Gangliosides of the neuron. Trends Neurosci 4, 169-174.
28. Lee S. J., Liyanage U., Bickel P. E., Xia W., Lansbury P. T. Jr and Kosik K. S. (1998) A detergent-insoluble membrane compartment contains Aβ in vivo. Nature Med. 4, 730-734.
29. London E. and Brown DA. (2000) Insolubility of lipids in triton X-100: physical origin and relationship to sphingolipid/cholesterol membrane domains (rafts). Biochim. Biophys. Acta 1508, 182-195.
30. Masserini M., Palestini P. and Pitto M. (1999) Glycolipid-enriched caveolae and caveolae-like domains in the nervous system. J. Neurochem. 73, 1-11.
31. Matsuzaki K. and Horikiri C. (1999) Interactions of amyloid β-petide (1-40) with ganglioside-containing membranes. Biochemistry 38, 4137-4142.
32. McKhann G., Drachman D., Folstein M., Katzman R., Price D. and Stadlan E. M. (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology 34, 939-944.
33. van Meer G. (2002) The different hues of lipid rafts. Science 296, 855-857.
34. van Meer G. and Lisman Q. (2002) Sphingolipid transport: rafts and translocators. J. Biol. Chem. 277, 25 855-25 858.
35. Mirra S. S., Heyman A. and McKeel D. (1991) The consortium to establish a registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41, 479-486.
36. Molander M., Berthold C. H., Persson H. and Fredman P. (2000) Immunostaining of ganglioside GD1b, GD3 and GM1 in rat cerebellum: cellular layer and cell type specific associations. J. Neurosci. Res. 60, 531-542.
37. Nixon R. A. (2004) Niemann-Pick Type C disease and Alzheimer's disease: the APP-endosome connection fattens up. Am. J. Pathol. 164, 757-761.
38. Ohvo-Rekilä H., Ramstedt B., Leppimaki P. and Slotte J. P. (2002) Cholesterol interactions with phospholipids in membranes. Prog. Lipid Res. 41, 66-97.
39. Ortengren U., Karlsson M., Blazic N., Blomqvist M., Nyström F., Gustavsson J., Fredman P. and Strålfors P. (2004) Lipids and glycosphingolipids in Caveolae and surrounding plasma membranes of primary rat adipocytes. Eur J. Biochem. 271, 2028-2036.
40. Palestini P., Botto L., Guzzi F., Calvi C., Ravasi D. and Masserini M. and Pitto M. (2002) Developmental changes in the protein composition of sphingolipid- and cholesterol-enriched membrane domains of rat cerebellar granule cells. J. Neurosci. Res. 67, 729-738.
41. Pernber Z., Molander-Melin M., Berthold C. H., Hansson E. and Fredman P. (2002) Expression of the myelin and oligodendrocyte progenitor marker sulfatide in neurons and astrocytes of adult rat brain. J. Neurosci. Res. 69, 86-93.
42. Peters M., Mehlhorn I., Barber K. and Grant C. (1984) Evidence of a distribution difference between two gangliosides in bilayer membranes. Biochim. Biophys. Acta 778, 419-428.
43. Pike L. J., Han X.Chung K. N. and Gross R. W. (2002) Lipid rafts are enriched in arachidonic acid and plasmenylethanolamine and their composition is dependent of caveolin-1 expression: a quantitative electrospray ionization/mass spectrometric analysis. Biochemistry 41, 2075-2088.
44. Prinetti A., Chigorno V., Tettamanti G. and Sonnino S. (2000) Sphingolipid-enriched membrane domains from rat cerebellar granule cells differentiated in culture. A compositional study. J. Biol. Chem. 275, 11 658-11 665.
45. Prinetti A., Chigorno V., Prioni S., Loberto N., Marano N., Tettamanti G. and Sonnino S. (2001) Changes in the lipid turnover, composition, and organization as sphingolipid-enriched membrane domains, in rat cerebellar granule cells developing in vitro. J. Biol. Chem. 276, 21 136-21 145.
46. 2+-ATPase in nerve terminals: a contribution to the possible functional role of gangliosides. Indian J. Biochem. Biophys. 27, 420-424.
47. Selkoe D. J. (1994) Amyloid beta-protein precursor: new clues to the genesis of Alzheimer's disease. Curr. Opin. Neurobiol. 4, 708-716.
48. Simons K. and Ehehalt R. (2002) Cholesterol, lipid rafts, and disease. J. Clin. Invest. 110, 597-603.
49. Simons K. and Ikonen E. (1997) Functional rafts in cell membranes. Nature 387, 569-572.
50. Simons K. and Ikonen E. (2000) How cells handle cholesterol. Science 290, 1721-1725.
51. Skipski V. P. (1975) Thin-layer chromatography of neutral glycosphingolipids, in Methods in Enzymology (Colowick, S. P. and Kaplan, N. O. eds), pp. 396-425. Academic Press, New York.
52. Small D. H., Mok S. S. and Bornstein J. C. (2001) Alzheimer's disease and Abeta toxicity: from top to bottom. Ann. Rev. Neurosci. 2, 595-598.
53. Svennerholm L. and Fredman P. (1980) A procedure for the quantitative isolation of brain gangliosides. Biochim. Biophys. Acta 617, 97-109.
54. Svennerholm L. and Gottfries C. G. (1994) Membrane lipids, selectively diminished in Alzheimer brains, suggest synapse loss as a primarily event in early-onset form (type I) and demyelination in late-onset form (type II). J. Neurochem. 62, 1039-1047.
55. Svennerholm L. and Vanier M. T. (1972) The distribution of lipids in the human nervous system. II. Lipid composition of human fetal and infant brain. Brain Res. 47, 457-468.
56. Svennerholm L., Bostrom K., Fredman P., Mansson J.-E., Rosengren B. and Rynmark B.-M. (1989) Human brain gangliosides: developmental changes from early fetal age to advanced age. Biochim. Biophys. Acta 1005, 109-117.
57. Svennerholm L., Boström K., Helander C. G. and Jungbjer B. (1991) Membrane lipids in the aging brain. J. Neurochem. 56, 2051-2059.
58. Svennerholm L., Boström K., Jungbjer B. and Olsson L. (1994) Membrane lipid of adult human brain: lipid composition of frontal and temporal lobe in subjects of age 20-100 years. J. Neurochem. 63, 1802-1811.
59. Thompson P., Hayashi K., de Zubicaray G. et al. (2003) Dynamics of gray matter loss in Alzheimer's disease. J. Neurosci. 23, 994-1005.
60. Vanier M. T. (1999) Lipid changes in Niemann-Pick disease type C brain: personal experience and review of the literature. Neurochem. Res. 24, 481-489.
61. Walkley S. U., Zervas M. and Wiseman S. (2000) Gangliosides as modulators of dendritogenesis in normal and storage disease-affected pyramidal neurons. Cereb. Cortex 10, 1028-1037.
62. Wang S. S.-S., Rymer D. L. and Good T. A. (2001) Reduction in cholesterol and sialic acid content protects cells from the toxic effects of β-amyloid peptides. J. Biol. Chem. 276, 42 027-42 034.
63. Yamamoto N., Hasegawa K., Matsuzaki K., Naiki H. and Yanagisawa K. (2004) Environment- and mutation-dependent aggregation behavior of Alzheimer amyloid β-protein. J. Neurochem. 90, 62-69.
64. Yanagisawa K. and Ihara Y. (1998) GM1 ganglioside-bound amyloid beta-protein in Alzheimer's disease brain. Neurobiol. Aging 19, S65-S67.
65. Yanagisawa K., Odaka A., Suzuki N. and Ihara Y. (1995) GM1 ganglioside-bound amyloid β-protein (Aβ): a possible form of preamyloid in Alzheimer's disease. Nat. Med. 1, 1062-1066.